UnknownPhase 2

Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

China36 participantsStarted 2023-05-08

Plain-language summary

This is a prospective, single arm, single center study to evaluate the efficacy and safety of Duvelisib combined with Chidamide in the treatment of newly diagnosed peripheral T-cell lymphoma.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓.Age: 18-70 Years (Contains boundary values 18 and 70);

Exclusion criteria

✕.Subjects who have previously received systemic treatment for lymphoma or currently undergoing anticancer treatment;

What they're measuring

Safety: Hematologic and non-hematologic toxicities (NCI CTCAE v5.0)

Timeframe: from the initiation of the first dose to 28 days after the last dose

Trial details

NCT IDNCT05976997

SponsorLiling Zhang

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12

Contact for this trial

Liling Zhang, M.D

15871725926 15871725926lily1228@sina.com

View on ClinicalTrials.gov More Newly Diagnosed Peripheral T-cell Lymphoma trials